EG20472A - Process for preparing of golanthamine derivatives a acitylcholinesterase inhibitors - Google Patents

Process for preparing of golanthamine derivatives a acitylcholinesterase inhibitors

Info

Publication number: EG20472A
Authority: EG; Egypt
Prior art keywords: hydrogen; golanthamine; acitylcholinesterase; inhibitors; derivatives
Prior art date: 1993-10-15

Application number

EG64194A

Other languages

English (en)

Inventor

Raymond W Kosley Jr

Original Assignee

Hoechst Marion Roussel Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-10-15

Filing date

1994-10-13

Publication date

1999-05-31

1994-10-13 Application filed by Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel Inc

1999-05-31 Application granted granted Critical

1999-05-31 Publication of EG20472A publication Critical patent/EG20472A/xx

Links

239000003112 inhibitor Substances 0.000 title 1
238000004519 manufacturing process Methods 0.000 title 1
239000001257 hydrogen Substances 0.000 abstract 6
229910052739 hydrogen Inorganic materials 0.000 abstract 6
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 4
125000004457 alkyl amino carbonyl group Chemical group 0.000 abstract 2
150000002431 hydrogen Chemical class 0.000 abstract 2
229920006395 saturated elastomer Polymers 0.000 abstract 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000001475 halogen functional group Chemical group 0.000 abstract 1
125000000623 heterocyclic group Chemical group 0.000 abstract 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
230000003287 optical effect Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

EG64194A 1993-10-15 1994-10-13 Process for preparing of golanthamine derivatives a acitylcholinesterase inhibitors EG20472A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/137,440 US6323195B1 (en)	1993-10-15	1993-10-15	Galanthamine derivatives as acetylcholinesterase inhibitors

Publications (1)

Publication Number	Publication Date
EG20472A true EG20472A (en)	1999-05-31

Family

ID=22477446

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EG64194A EG20472A (en)	1993-10-15	1994-10-13	Process for preparing of golanthamine derivatives a acitylcholinesterase inhibitors

Country Status (23)

Country	Link
US (2)	US6323195B1 (de)
EP (2)	EP0653427B1 (de)
JP (1)	JP2664344B2 (de)
KR (1)	KR0169114B1 (de)
CN (1)	CN1039911C (de)
AT (1)	ATE212348T1 (de)
AU (1)	AU696249B2 (de)
CA (1)	CA2118174C (de)
CZ (1)	CZ287071B6 (de)
DE (1)	DE69429708T2 (de)
DK (1)	DK0653427T3 (de)
EG (1)	EG20472A (de)
ES (1)	ES2171428T3 (de)
FI (1)	FI108723B (de)
IL (1)	IL111274A (de)
NO (1)	NO310415B1 (de)
NZ (1)	NZ264683A (de)
PL (1)	PL177730B1 (de)
PT (1)	PT653427E (de)
RO (1)	RO114133B1 (de)
RU (1)	RU2114850C1 (de)
TW (1)	TW363969B (de)
ZA (1)	ZA948062B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9514821D0 (en) *	1995-07-19	1995-09-20	Sod Conseils Rech Applic	Galanthamine derivatives
AT403803B (de) *	1996-04-19	1998-05-25	Sanochemia Ltd	Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
WO2000030446A1 (en) *	1998-11-23	2000-06-02	Bonnie Davis	Dosage formulations for acetylcholinesterase inhibitors
EP1140105B1 (de)	1998-12-24	2003-10-22	Janssen Pharmaceutica N.V.	Galantamin-zusammensetzung mit gesteuerter freisetzung
US8603546B2 (en) *	1999-01-11	2013-12-10	Herbaceuticals Inc.	Herbal supplement for increased muscle strength and endurance for athletes
WO2000041540A2 (en) *	1999-01-11	2000-07-20	Atanas Russinov Djananov	Herbal supplement for increased muscle strength and endurance for athletes
US6372760B1 (en) *	1999-03-31	2002-04-16	Eisai Co., Ltd.	Stabilized composition comprising antidementia medicament
WO2001030318A1 (en) *	1999-10-26	2001-05-03	Janssen Pharmaceutica N.V.	Oral solution containing galanthamine and a sweetening agent
AU780012B2 (en) *	1999-12-10	2005-02-24	Bonnie Davis	Analogs of galanthamine and lycoramine as modulators of nicotinic receptors
CN1380883A (zh)	2000-03-31	2002-11-20	萨诺化学药物股份公司	雪花胺的新衍生物和类似物
US20030162770A1 (en) *	2002-02-22	2003-08-28	Davis Bonnie M.	Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
US20050143350A1 (en) *	2003-11-19	2005-06-30	Seed John C.	Combination drug therapy to treat obesity
CA2552114A1 (en) *	2003-12-31	2005-07-21	Actavis Group Hf	Solid dosage formulations of galantamine
US20050191349A1 (en) *	2003-12-31	2005-09-01	Garth Boehm	Galantamine formulations
EP1779867A4 (de) *	2004-07-01	2009-12-02	Eisai R&D Man Co Ltd	Mittel zur förderung der nervenreveneration
DK1895994T3 (da) *	2005-05-13	2010-12-20	Alza Corp	Multilagsmedikamentleveringssystem med barriere mod reservoirmaterialeflow
US20080188510A1 (en) *	2005-05-23	2008-08-07	Eisai R & D Management Co., Ltd.	Novel methods using zonisamide
EP1777222A1 (de)	2005-09-22	2007-04-25	Galantos Pharma GmbH	Cholinesterase Inhibitoren mit erhöter Blut Hirn Schranke Permeabilität zur Behandlung von kognitiven Störungen
ATE473219T1 (de) *	2005-09-22	2010-07-15	Galantos Pharma Gmbh	Cholinerge enhancer mit verbesserter durchgängigkeit durch die blut-hirn-schranke zur behandlung von krankheiten, die mit kognitiven störungen einhergehen
US20090253654A1 (en)	2005-09-22	2009-10-08	Galantos Pharma Gmbh	Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
WO2007035941A2 (en) *	2005-09-23	2007-03-29	Alza Corporation	Transdermal galantamine delivery system
EP2137192B8 (de)	2008-04-14	2014-06-11	Neurodyn Life Sciences Inc.	Galantaminderivate als Prodrug-Verbindungen zur Behandlung humaner Hirnerkrankungen
US20120184532A1 (en) *	2009-07-23	2012-07-19	Shire Llc	Galantamine amino acid and peptide prodrugs and uses thereof
WO2013160728A1 (en)	2012-04-26	2013-10-31	Alma Mater Studiorum - Universita' Di Bologna	Dual targeting compounds for the treatment of alzheimer's disease
EP3628315A1 (de)	2018-09-28	2020-04-01	Université de Caen Normandie	Kombination aus acetylcholinesterase-inhibitor und 5-ht4-rezeptoragonist als neuroprotektives mittel zur behandlung von neurodegenerativen krankheiten
CN113292420A (zh) *	2021-05-27	2021-08-24	神隆医药（常熟）有限公司	加兰他敏中间体原料2-溴-5-羟基-4-甲氧基苯甲酸回收方法
US12551491B1 (en) *	2025-07-23	2026-02-17	Alpha Cognition Inc.	Dosage regimens for benzgalantamine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL122665B1 (en)	1978-11-21	1982-08-31	Edinen Zentar Chim	Process for preparing novel dienones of narvedine type and their derivatives
US4751306A (en) *	1985-09-09	1988-06-14	E. I. Du Pont De Nemours And Company	Imide intermediates for the preparation of analgesic and/or antagonist octahydrobenzofuroisoquinolines
US4663318A (en)	1986-01-15	1987-05-05	Bonnie Davis	Method of treating Alzheimer's disease
US6150354A (en) *	1987-01-15	2000-11-21	Bonnie Davis	Compounds for the treatment of Alzheimer's disease
DE3856594D1 (de) *	1987-05-04	2008-11-27	Bonnie Davis	Mittel zur behandlung der alzheimer-krankheit
NL8800350A (nl)	1988-02-12	1989-09-01	Stichting Biomedical Research	Synthetische galanthamine-derivaten, werkwijze voor het bereiden daarvan, en farmaceutische samenstellingen.
EP0344980A3 (de) *	1988-06-01	1991-05-15	Smithkline Beecham Corporation	Alpha-adrenergische Rezeptorantagonisten
DE69229781T2 (de)	1991-05-14	2000-01-05	Ernir Snorrason	Behandlung des ermüdungssyndroms mit cholinesteraseinhibitoren
US5153193A (en)	1991-10-01	1992-10-06	Hoechst-Roussel Pharmaceuticals Incorporated	Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
US5231093A (en) *	1991-10-01	1993-07-27	Hoechst-Roussel Pharmaceuticals Incorporated	Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs

1993
- 1993-10-15 US US08/137,440 patent/US6323195B1/en not_active Expired - Lifetime
1994
- 1994-10-10 EP EP94115959A patent/EP0653427B1/de not_active Expired - Lifetime
- 1994-10-10 PT PT94115959T patent/PT653427E/pt unknown
- 1994-10-10 DE DE69429708T patent/DE69429708T2/de not_active Expired - Lifetime
- 1994-10-10 AT AT94115959T patent/ATE212348T1/de active
- 1994-10-10 ES ES94115959T patent/ES2171428T3/es not_active Expired - Lifetime
- 1994-10-10 EP EP00107570A patent/EP1020470A3/de not_active Withdrawn
- 1994-10-10 DK DK94115959T patent/DK0653427T3/da active
- 1994-10-13 EG EG64194A patent/EG20472A/xx active
- 1994-10-13 RU RU94036448A patent/RU2114850C1/ru active
- 1994-10-13 NZ NZ264683A patent/NZ264683A/en not_active IP Right Cessation
- 1994-10-13 IL IL11127494A patent/IL111274A/xx not_active IP Right Cessation
- 1994-10-13 FI FI944821A patent/FI108723B/fi not_active IP Right Cessation
- 1994-10-14 AU AU75814/94A patent/AU696249B2/en not_active Expired
- 1994-10-14 CZ CZ19942546A patent/CZ287071B6/cs not_active IP Right Cessation
- 1994-10-14 KR KR1019940026303A patent/KR0169114B1/ko not_active Expired - Lifetime
- 1994-10-14 CN CN94117060A patent/CN1039911C/zh not_active Expired - Lifetime
- 1994-10-14 CA CA002118174A patent/CA2118174C/en not_active Expired - Lifetime
- 1994-10-14 NO NO19943893A patent/NO310415B1/no not_active IP Right Cessation
- 1994-10-14 TW TW083109526A patent/TW363969B/zh not_active IP Right Cessation
- 1994-10-14 ZA ZA948062A patent/ZA948062B/xx unknown
- 1994-10-14 RO RO94-01669A patent/RO114133B1/ro unknown
- 1994-10-14 PL PL94305456A patent/PL177730B1/pl unknown
- 1994-10-17 JP JP6250778A patent/JP2664344B2/ja not_active Expired - Fee Related
1995
- 1995-05-22 US US08/445,921 patent/US5777108A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
JP2664344B2 (ja)	1997-10-15
CN1039911C (zh)	1998-09-23
PL305456A1 (en)	1995-04-18
EP1020470A3 (de)	2000-07-26
CZ254694A3 (en)	1995-09-13
EP0653427A1 (de)	1995-05-17
AU696249B2 (en)	1998-09-03
IL111274A0 (en)	1994-12-29
CN1111245A (zh)	1995-11-08
RU2114850C1 (ru)	1998-07-10
NO943893L (no)	1995-04-18
KR950011443A (ko)	1995-05-15
ES2171428T3 (es)	2002-09-16
NZ264683A (en)	1998-03-25
ATE212348T1 (de)	2002-02-15
CZ287071B6 (en)	2000-08-16
NO310415B1 (no)	2001-07-02
EP0653427B1 (de)	2002-01-23
US5777108A (en)	1998-07-07
PL177730B1 (pl)	2000-01-31
DE69429708T2 (de)	2002-08-29
CA2118174A1 (en)	1995-04-16
DK0653427T3 (da)	2002-04-15
FI108723B (fi)	2002-03-15
EP1020470A2 (de)	2000-07-19
RO114133B1 (ro)	1999-01-29
DE69429708D1 (de)	2002-03-14
JPH07188240A (ja)	1995-07-25
KR0169114B1 (ko)	1999-01-15
NO943893D0 (no)	1994-10-14
US6323195B1 (en)	2001-11-27
RU94036448A (ru)	1996-09-10
FI944821L (fi)	1995-04-16
AU7581494A (en)	1995-05-04
TW363969B (en)	1999-07-11
ZA948062B (en)	1995-06-06
CA2118174C (en)	2000-01-18
FI944821A0 (fi)	1994-10-13
IL111274A (en)	2000-11-21
PT653427E (pt)	2002-06-28

Publication	Publication Date	Title
PL305456A1 (en)	1995-04-18	Galantamine derivatives, method of obtaining them and pharmaceutical composition
HU9300723D0 (en)	1993-06-28	Methylene-oxindole derivatives and method for producing them
EG20747A (en)	2000-01-31	Method for preparing galanthamine derivatives as acetylcholinesterase inhibitors
HUT71482A (en)	1995-11-28	4,1-benzoxazepine derivatives, process for preparing them and pharmaceutical compositions containing them
TW290546B (de)	1996-11-11
AU1121492A (en)	1992-10-01	Derivatives of substituted imidazol-2-one and process for their preparation
HU9501664D0 (en)	1995-08-28	New cephem compounds
GR3023827T3 (en)	1997-09-30	Indole-sulfonamides as antitumor agents.
TW254937B (en)	1995-08-21	Benzocycloheptene derivative and process for preparation thereof
GB2282810A (en)	1995-04-19	Process for the preparation of clavulanic acid